Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9284MR)

This product GTTS-WQ9284MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8165MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ14328MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ15032MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ14488MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ13307MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ862MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ2503MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ11780MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW